Patient Square Capital’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Patient Square Capital’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,341	Closed	-$523K	–	27
2025 Q2	$523K	Buy	6,341 +1,200	+23%	+$78K	0.19%	19
2025 Q1	$406K	Buy	+5,141	New	+$633K	0.17%	19

Other funds holding YARW

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Patient Square Capital's YARW Position: Q3 2025 in Review

Patient Square Capital sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q3 2025, closing a stake of 6,341 shares — an estimated $523K sold.

Patient Square Capital first reported a position in YARW in Q1 2025 and held it in 2 quarters. The position peaked at $523K in Q2 2025. 34 funds tracked by Wall St. Rank hold YARW as of Q3 2025.

Patient Square Capital reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q3 2025 after selling out during the quarter.
Patient Square Capital sold 6,341 Yarrow Bioscience, Inc. Common Stock shares in Q3 2025, an estimated $523K.
Patient Square Capital first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2025 and held it in 2 quarters.
Patient Square Capital's Yarrow Bioscience, Inc. Common Stock position peaked at $523K in Q2 2025.
34 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q3 2025.

Based on Patient Square Capital's 13F filing for Q3 2025, filed 10 Nov 2025.